Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...

Cellipont Bioservices and Secretome Therapeutics are set to enter a collaboration in the manufacture of the latter’s cellular therapy, STM-01. The collaboration will see Cellipont offering technology ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, diagnosis and management of diabetes in general practice. This series showcases ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data ...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome ...

Cedars-Sinai shared the story of a Hollywood writer who kept his appointment for mitral valve surgery right after escaping ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

DelveInsight's Heart failure with Reduced Ejection Fraction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.